A BILL 
To amend title XVIII of the Social Security Act to require 
drug manufacturers to pay a Medicare part D rebate 
for certain drugs if the price of such drugs increases 
faster than inflation. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Pharmaceutical Re-
4
bates for Excessive Pricing Above Inflation Act’’ or the 
5
‘‘Pharmaceutical REPAI Act’’. 
6
22:21 Oct 08, 2019
H4619
2 
•HR 4619 IH
SEC. 2. MEDICARE PART D PRESCRIPTION DRUG INFLA-
1
TION REBATE BY MANUFACTURERS. 
2
Part D of title XVIII of the Social Security Act is 
3
amended by inserting after section 1860D–14A (42 
4
U.S.C. 1395w–114a) the following new section: 
5
‘‘SEC. 1860D–14B. MANUFACTURER REBATE FOR CERTAIN 
6
DRUGS WITH PRICES INCREASING FASTER 
7
THAN INFLATION. 
8
‘‘(a) IN GENERAL.—Subject to the provisions of this 
9
section, in order for coverage to be available under this 
10
part for a part D rebatable drug of a manufacturer dis-
11
pensed during an applicable year, the manufacturer must 
12
have entered into and have in effect an agreement de-
13
scribed in subsection (b). For purposes of this section the 
14
term ‘applicable year’ means a year beginning with 2022. 
15
‘‘(b) AGREEMENTS.— 
16
‘‘(1) TERMS OF AGREEMENT.—An agreement 
17
described in this subsection, with respect to a manu-
18
facturer of a part D rebatable drug, is an agreement 
19
under which the following applies: 
20
‘‘(A) SECRETARIAL PROVISION OF INFOR-
21
MATION.—Not later than 9 months after the 
22
end of each applicable year with respect to 
23
which the agreement is in effect, the Secretary, 
24
for the part D rebatable drug of the manufac-
25
22:21 Oct 08, 2019
H4619
3 
•HR 4619 IH
turer, reports to the manufacturer the following 
1
for such year: 
2
‘‘(i) Information on the total units (as 
3
defined in subsection (g)(2)) dispensed for 
4
each dosage form and strength with re-
5
spect to such part D rebatable drug and 
6
year. 
7
‘‘(ii) Information on the amount (if 
8
any) of the excess average manufacturer 
9
price increase described in subsection 
10
(c)(1)(B) for each dosage form and 
11
strength with respect to such drug and 
12
year. 
13
‘‘(iii) The rebate amount specified 
14
under subsection (c) for each dosage form 
15
and strength with respect to such drug and 
16
year. 
17
‘‘(B) MANUFACTURER
REQUIREMENTS.— 
18
For each applicable year with respect to which 
19
the agreement is in effect, the manufacturer of 
20
the part D rebatable drug, for each dosage 
21
form and strength with respect to such drug, 
22
not later than 30 days after the date of receipt 
23
from the Secretary of the information described 
24
in subparagraph (A) for such year, provides to 
25
22:21 Oct 08, 2019
H4619
4 
•HR 4619 IH
the Secretary a rebate that is equal to the 
1
amount specified in subsection (c) for such dos-
2
age form and strength with respect to such 
3
drug for such year. 
4
‘‘(2) LENGTH OF AGREEMENT.— 
5
‘‘(A) IN GENERAL.—An agreement under 
6
this section, with respect to a part D rebatable 
7
drug, shall be effective for an initial period of 
8
not less than one year and shall be automati-
9
cally renewed for a period of not less than one 
10
year unless terminated under subparagraph 
11
(B). 
12
‘‘(B) TERMINATION.— 
13
‘‘(i) BY SECRETARY.—The Secretary 
14
may provide for termination of an agree-
15
ment under this section for violation of the 
16
requirements of the agreement or other 
17
good cause shown. Such termination shall 
18
not be effective earlier than 60 days after 
19
the date of notice of such termination. The 
20
Secretary shall provide, upon request, a 
21
manufacturer with a hearing concerning 
22
such a termination, but such hearing shall 
23
not delay the effective date of the termi-
24
nation. 
25
22:21 Oct 08, 2019
H4619
5 
•HR 4619 IH
‘‘(ii) BY A MANUFACTURER.—A man-
1
ufacturer may terminate an agreement 
2
under this section for any reason. Any 
3
such termination shall not be effective 
4
until the year beginning at least 60 days 
5
after the date the manufacturer provides 
6
notice to the Secretary. 
7
‘‘(C) EFFECTIVENESS OF TERMINATION.— 
8
Any termination under this paragraph shall not 
9
affect rebates due under the agreement under 
10
this section before the effective date of its ter-
11
mination. 
12
‘‘(D) DELAY
BEFORE
REENTRY.—In the 
13
case of any agreement under this section with 
14
a manufacturer which is terminated in a plan 
15
year, another such agreement with the manu-
16
facturer (or a successor manufacturer) may not 
17
be entered into before the subsequent plan year, 
18
unless the Secretary finds good cause for an 
19
earlier reinstatement of such an agreement. 
20
‘‘(3) INFORMATION.—For purposes of carrying 
21
out this section, the Secretary shall use information 
22
submitted 
by 
manufacturers 
under 
section 
23
1927(b)(3). 
24
‘‘(c) REBATE AMOUNT.— 
25
22:21 Oct 08, 2019
H4619
6 
•HR 4619 IH
‘‘(1) IN GENERAL.—For purposes of this sec-
1
tion, the amount specified in this subsection for a 
2
dosage form and strength with respect to a part D 
3
rebatable drug and applicable year is, subject to sub-
4
paragraphs (B) and (C) of paragraph (3), the 
5
amount equal to the product of— 
6
‘‘(A) the total average number of units 
7
weighted by, and dispensed for, such dosage 
8
form and strength with respect to such part D 
9
rebatable drug and year; and 
10
‘‘(B) the amount (if any) by which— 
11
‘‘(i) the average manufacturer price 
12
(as defined in subsection (g)) paid for such 
13
dosage form and strength with respect to 
14
such part D rebatable drug during the 
15
year; exceeds 
16
‘‘(ii) the inflation-adjusted payment 
17
amount determined under paragraph (2) 
18
for such dosage form and strength with re-
19
spect to such part D rebatable drug during 
20
the year. 
21
‘‘(2) DETERMINATION OF INFLATION-ADJUSTED 
22
PAYMENT AMOUNT.—The inflation-adjusted payment 
23
amount determined under this paragraph for a dos-
24
age form and strength with respect to a part D 
25
22:21 Oct 08, 2019
H4619
7 
•HR 4619 IH
rebatable drug for an applicable year, subject to sub-
1
paragraphs (A) and (D) of paragraph (3), is— 
2
‘‘(A) the average manufacturer price paid 
3
for such dosage form and strength with respect 
4
to such drug in the payment amount bench-
5
mark year (as defined in subsection (g)(3)); in-
6
creased by 
7
‘‘(B) the percentage by which the rebate 
8
period CPI–U (as defined in subsection (g)(5)) 
9
for the applicable year exceeds the benchmark 
10
period CPI–U (as defined in subsection (g)(4)). 
11
‘‘(3) SPECIAL TREATMENT OF CERTAIN DRUGS 
12
AND EXEMPTION.— 
13
‘‘(A) SUBSEQUENTLY APPROVED DRUGS.— 
14
In the case of a part D rebatable drug first ap-
15
proved by the Food and Drug Administration 
16
after January 1, 2016, subparagraph (A) of 
17
paragraph (2) shall be applied as if the term 
18
‘payment amount benchmark year’ were defined 
19
under subsection (g)(3) as the first year begin-
20
ning after the day on which the drug was first 
21
marketed and subparagraph (B) of paragraph 
22
(2) shall be applied as if the term ‘benchmark 
23
period CPI–U’ were defined under subsection 
24
(g)(4) as if the reference to ‘January 2016’ 
25
22:21 Oct 08, 2019
H4619
8 
•HR 4619 IH
under such subsection were a reference to ‘Jan-
1
uary of the first year beginning after the date 
2
on which the drug was first marketed by any 
3
manufacturer’. 
4
‘‘(B) EXEMPTION FOR SHORTAGES.—The 
5
Secretary may reduce or waive the rebate under 
6
paragraph (1) with respect to a part D rebata-
7
ble drug in the case of a shortage of such drug 
8
or other exigent circumstances, as determined 
9
by the Secretary. 
10
‘‘(C) TREATMENT
OF
NEW
FORMULA-
11
TIONS.— 
12
‘‘(i) IN GENERAL.—In the case of a 
13
part D rebatable drug that is a line exten-
14
sion of a single source drug or an inno-
15
vator multiple source drug that is an oral 
16
solid dosage form, the Secretary shall es-
17
tablish a formula for determining the 
18
amount specified in this subsection with 
19
respect to such part D rebatable drug and 
20
an applicable year with consideration of 
21
the single source drug or an innovator 
22
multiple source drug. 
23
‘‘(ii) LINE EXTENSION DEFINED.—In 
24
this subparagraph, the term ‘line exten-
25
22:21 Oct 08, 2019
H4619
9 
•HR 4619 IH
sion’ means, with respect to a part D reba-
1
table drug, a new formulation of the drug 
2
(as determined by the Secretary), such as 
3
an extended release formulation, but does 
4
not include an abuse-deterrent formulation 
5
of the drug (as determined by the Sec-
6
retary), regardless of whether such abuse- 
7
deterrent formulation is an extended re-
8
lease formulation. 
9
‘‘(d) REBATE DEPOSITS.—Amounts paid as rebates 
10
under subsection (c) shall be deposited into the Medicare 
11
Prescription Drug Account in the Federal Supplementary 
12
Medical Insurance Trust Fund established under section 
13
1841. 
14
‘‘(e) CIVIL MONEY PENALTY.—In the case of a man-
15
ufacturer of a part D rebatable drug with an agreement 
16
in effect under this section who has failed to comply with 
17
the terms of the agreement under subsection (b)(1)(B) 
18
with respect to such drug for an applicable year, the Sec-
19
retary may impose a civil money penalty on such manufac-
20
turer in an amount equal to 125 percent of the amount 
21
specified in subsection (c) for such drug for such year. 
22
The provisions of section 1128A (other than subsections 
23
(a) (with respect to amounts of penalties or additional as-
24
sessments) and (b)) shall apply to a civil money penalty 
25
22:21 Oct 08, 2019
H4619
10 
•HR 4619 IH
under this subsection in the same manner as such provi-
1
sions apply to a penalty or proceeding under section 
2
1128A(a). 
3
‘‘(f) JUDICIAL REVIEW.—There shall be no judicial 
4
review of the following: 
5
‘‘(1) The determination of units under this sec-
6
tion. 
7
‘‘(2) The determination of whether a drug is a 
8
part D rebatable drug under this section. 
9
‘‘(3) The calculation of the rebate amount 
10
under this section. 
11
‘‘(g) DEFINITIONS.—In this section: 
12
‘‘(1) PART D REBATABLE DRUG DEFINED.— 
13
‘‘(A) IN
GENERAL.—The term ‘part D 
14
rebatable drug’ means a drug or biological that 
15
would (without application of this section) be a 
16
covered part D drug, except such term shall, 
17
with respect to an applicable year, not include 
18
such a drug or biological if the average total 
19
cost under a prescription drug plan under this 
20
part or MA–PD plan under part C for such 
21
year per individual who uses such a drug or bi-
22
ological, as determined by the Secretary, are 
23
less than, subject to subparagraph (B), $100, 
24
as determined by the Secretary using the most 
25
22:21 Oct 08, 2019
H4619
11 
•HR 4619 IH
recent data available or, if data is not available, 
1
as estimated by the Secretary. 
2
‘‘(B) INCREASE.—The dollar amount ap-
3
plied under subparagraph (A)— 
4
‘‘(i) for 2023, shall be the dollar 
5
amount specified under such subparagraph 
6
for 2022, increased by the percentage in-
7
crease in the consumer price index for all 
8
urban consumers (United States city aver-
9
age) as of January of 2022; and 
10
‘‘(ii) for a subsequent year, shall be 
11
the dollar amount specified in this sub-
12
paragraph (or subparagraph (A)) for the 
13
previous year, increased by the percentage 
14
increase in the consumer price index for all 
15
urban consumers (United States city aver-
16
age) as of January of the previous year. 
17
Any dollar amount specified under this sub-
18
paragraph that is not a multiple of $10 shall be 
19
rounded to the nearest multiple of $10. 
20
‘‘(2) UNIT DEFINED.—The term ‘unit’ means, 
21
with respect to a part D rebatable drug, the lowest 
22
identifiable quantity (such as a capsule or tablet, 
23
milligram of molecules, or grams) of the part D 
24
rebatable drug that is dispensed to individuals en-
25
22:21 Oct 08, 2019
H4619
12 
•HR 4619 IH
rolled under a prescription drug plan under this part 
1
or an MA–PD plan under part C. 
2
‘‘(3) PAYMENT AMOUNT BENCHMARK YEAR.— 
3
The term ‘payment amount benchmark year’ means 
4
the year beginning January 1, 2016. 
5
‘‘(4) BENCHMARK
PERIOD
CPI–U.—The term 
6
‘benchmark period CPI–U’ means the consumer 
7
price index for all urban consumers (United States 
8
city average) for January 2016. 
9
‘‘(5) REBATE PERIOD CPI–U.—The term ‘rebate 
10
period CPI–U’ means, with respect to an applicable 
11
year, the consumer price index for all urban con-
12
sumers (United States city average) for January of 
13
such year. 
14
‘‘(6) AVERAGE
MANUFACTURER
PRICE.—The 
15
term ‘average manufacturer price’ has the meaning, 
16
with respect to a part D rebatable drug of a manu-
17
facturer for an applicable year, given such term in 
18
section 1927(k)(1), with respect to a covered out-
19
patient drug of a manufacturer for a rebate period 
20
under section 1927. For purposes of applying the 
21
previous sentence, with respect to a part D rebatable 
22
drug of a manufacturer and an applicable year, the 
23
Secretary shall use the information with respect to 
24
the average manufacturer price for such drug re-
25
22:21 Oct 08, 2019
H4619
13 
•HR 4619 IH
ported 
by 
the 
manufacturer 
under 
section 
1
1927(b)(3) with respect to each of the quarters in 
2
the applicable year and calculate an annual average 
3
manufacturer price for such applicable year as the 
4
average of such average manufacturer prices for 
5
each such quarter, weighted by units of such drug 
6
sold or dispensed with respect to such applicable 
7
year.’’. 
8
Æ 
22:21 Oct 08, 2019
H4619
